145 related articles for article (PubMed ID: 38236588)
1. Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022.
Xie JS; Kaur H; Tao B; Lee J; Solish D; Kohly R; Margolin E
JAMA Ophthalmol; 2024 Feb; 142(2):123-130. PubMed ID: 38236588
[TBL] [Abstract][Full Text] [Related]
2. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
Berkowitz ST; Groth SL; Gangaputra S; Patel S
JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. An Evaluation of Sex- and Gender-Based Analyses in Oncology Clinical Trials.
Hall M; Krishnanandan VA; Cheung MC; Coburn NG; Haas B; Chan KKW; Raphael MJ
J Natl Cancer Inst; 2022 Aug; 114(8):1186-1191. PubMed ID: 35477781
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
6. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis.
Chen KY; Borglund EM; Postema EC; Dunn AG; Bourgeois FT
Clin Trials; 2022 Aug; 19(4):442-451. PubMed ID: 35482320
[TBL] [Abstract][Full Text] [Related]
7. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
[TBL] [Abstract][Full Text] [Related]
8. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
Miller JE; Korn D; Ross JS
BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
[TBL] [Abstract][Full Text] [Related]
10. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
[TBL] [Abstract][Full Text] [Related]
11. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.
Loree JM; Anand S; Dasari A; Unger JM; Gothwal A; Ellis LM; Varadhachary G; Kopetz S; Overman MJ; Raghav K
JAMA Oncol; 2019 Oct; 5(10):e191870. PubMed ID: 31415071
[TBL] [Abstract][Full Text] [Related]
12. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.
Jenei K; Raymakers A; Meyers DE; Prasad V
J Cancer Policy; 2021 Dec; 30():100311. PubMed ID: 35559802
[TBL] [Abstract][Full Text] [Related]
13. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
14. ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.
Schwartz LM; Woloshin S; Zheng E; Tse T; Zarin DA
Ann Intern Med; 2016 Sep; 165(6):421-30. PubMed ID: 27294570
[TBL] [Abstract][Full Text] [Related]
15. Association Between Sex Composition and Publication Productivity of Journal Editorial and Professional Society Board Members in Ophthalmology.
Camacci ML; Lu A; Lehman EB; Scott IU; Bowie E; Pantanelli SM
JAMA Ophthalmol; 2020 May; 138(5):451-458. PubMed ID: 32215609
[TBL] [Abstract][Full Text] [Related]
16. Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysis.
Martinkova J; Quevenco FC; Karcher H; Ferrari A; Sandset EC; Szoeke C; Hort J; Schmidt R; Chadha AS; Ferretti MT
JAMA Netw Open; 2021 Sep; 4(9):e2124124. PubMed ID: 34515784
[TBL] [Abstract][Full Text] [Related]
17. Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study.
Dymanus KA; Butaney M; Magee DE; Hird AE; Luckenbaugh AN; Ma MW; Hall ME; Huelster HL; Laviana AA; Davis NB; Terris MK; Klaassen Z; Wallis CJD
Cancer; 2021 Sep; 127(17):3156-3162. PubMed ID: 34160824
[TBL] [Abstract][Full Text] [Related]
18. Race and Ethnicity Reporting and Enrollment Disparities in Clinical Trials Leading to FDA Approvals for Breast Cancer Between 2010 and 2020.
Nguyen RH; Silva Y; Lu J; Chen Z; Gadi V
Clin Breast Cancer; 2023 Aug; 23(6):591-597. PubMed ID: 37296063
[TBL] [Abstract][Full Text] [Related]
19. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
20. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
Seife C
JAMA Intern Med; 2015 Apr; 175(4):567-77. PubMed ID: 25664866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
